We found that an early remission of NT-proBNP within 3 months from baseline could improve the prognosis of CTD-PAH patients, while a delayed remission of NT-proBNP after 6 or 9 months from baseline could not, which demonstrated the key role of the time to achieve NT-proBNP remission in CTD-PAH prognosis prediction and the necessity of repeated measurements and trajectory analyses of NT-proBNP in the management of CTD-PAH patients. This evidence concerns the gene NPPB and pulmonary arterial hypertension.